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Abstract
Background Understanding the nature and time course of
the pharmacodynamic effects of attention-deficit/hyper-
activity disorder (ADHD) medications is useful. The
Cognitive Drug Research Computerized Battery of Tests
(CDR-CBT) is a 20-min battery of ten standardized, vali-
dated neuropsychometric tasks.
Objective This pilot study examined the sensitivity and
responsiveness of the CDR-CBT for assessing cognitive
function in adults with ADHD prior to and up to 16 h
postdose during treatment with lisdexamfetamine dimesy-
late (LDX) or mixed amphetamine salts immediate release
(MAS-IR; various generics available).
Methods This was a double-blind three-period crossover
study. Participants received LDX 50 mg/day, MAS-IR
20 mg/day, and placebo (*7 a.m.) for 7 days each in
randomized order. CDR-CBT was administered on day 1
of period 1 and day 7 of each period at scheduled times
between -0.5 (predose) and 16 h postdose. Composite
power of attention (PoA) score (sum of simple reaction
time, choice reaction time, and digit vigilance speed) was
the primary outcome measure. The Conners’ Adult ADHD
Rating Scales-Self-Report: Short Version (CAARS-S:S)
was administered at baseline and on day 1 of period 1, and
days 6 and 7 of each treatment period. Tertiary outcomes
included CDR-CBT composite continuity of attention
scores, its component task scores, cognitive reaction time,
and response variability scores. No inferential statistical
comparisons were conducted. Safety assessments included
adverse events (AEs) and vital signs.
Results This analysis included 18 participants (mean age
30.8 years); one withdrew because of AEs. Mean pretreat-
ment PoA scores were 1175.9–1361.2 ms, scores com-
mensurate with a normative age of [40 years. Maximum
reductions in PoA scores with LDX and MAS-IR occurred
at 5 h postdose at day 7 (least squares mean difference
[95 % CI] of -150.0 [-235.41 to -64.50] and -79.8
[-165.72 to 6.21] ms vs. placebo, respectively). CAARS-
S:S scores were unchanged with LDX and MAS-IR (vs.
placebo) at all postdose timepoints. Tertiary attention-
related CDR-CBT outcomes were sensitive to LDX and
MAS-IR (vs. placebo). Treatment-emergent AEs and vital
signs were consistent with previous studies in adult ADHD.
Conclusion In adults with ADHD, PoA scores indicated
impaired attention at baseline and response to treatment
with LDX and MAS-IR (vs. placebo), demonstrating value
for measuring the time course of pharmacologic treatment
effects.
1 Background
Impairments in neurocognitive executive function (EF),
including attention, self-regulation, and memory, are
important components of multiple psychiatric disorders,
including attention-deficit/hyperactivity disorder (ADHD)
[1, 2]. Both neuropsychometric and behavioral measures of
EF exhibit predictive relationships to ADHD diagnosis or
symptom severity [3–5].
The acute impact of psychostimulants on neurocognitive
processes in patients with ADHD is not well characterized.
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However, available data suggest that performance of neu-
rocognitive tasks, which are impaired in patients with
ADHD, have been shown to improve with pharmacologic
treatment of ADHD [6–8]. Treatment with methylpheni-
date helped normalize some aspects of neurocognitive
functioning in children with ADHD [6]. After a single dose
of methylphenidate 0.3 mg/kg, children with ADHD
showed improvements in sustained attention based on a
continuous performance task. Performance improvements
were accompanied by normalized activation in some, but
not all, brain regions (vs. normal controls) based on func-
tional magnetic resonance imaging scans [6]. Also, ado-
lescents and young adults with ADHD who took a
psychostimulant medication on the day of neuropsycho-
logic testing found that some aspects of neurocognitive
task performance improved, including sustained attention
and verbal learning, compared with untreated participants
[7]. Nevertheless, even with psychostimulant medication,
participants with ADHD continued to achieve lower
aggregate neurocognitive scores than normal controls,
likely due to continuing impairments in interference con-
trol and processing speed [7].
Pharmacodynamic drug effects on attention processes in
the postdosing period with psychostimulant treatment of
children with ADHD have also been demonstrated in
pediatric laboratory classroom studies and in an adult
simulated workplace environment [9–11]. The adult study
demonstrated improvement from baseline in patient-
reported executive neurocognitive processes, including
attention, based on the Brown Attention Deficit Disorder
Scale [12]; however, it was limited to a single objective
measure, and direct comparative immediate-release (IR)
versus extended-release (XR) data are lacking [10]. Addi-
tional objective pharmacodynamic measures that are sen-
sitive to repeated measures throughout the day would be
useful to better characterize the pharmacodynamic effects
of ADHD medications.
Certain limitations of conventional neurocognitive test-
ing, including the need for highly trained testing profes-
sionals, lengthy testing sessions, and numerous tasks [13,
14], serve as barriers to their use in pharmacodynamic
research, which requires repeated testing at defined post-
dose intervals, usually of 1–2 h. Moreover, conventional
testing in research settings may introduce variability in
procedures and stimulus presentation that limits detection
of group differences [13, 14]. To meet these challenges,
computerized testing methodologies have been developed,
particularly for assessing cognitive processes such as
attention. The Cognitive Drug Research Computerized
Battery of Tests (CDR-CBT) consists of ten standardized,
validated neuropsychometric tasks, and requires approxi-
mately 20 min to complete. The CDR-CBT has been val-
idated in several populations, having been demonstrated to
show convergent validity with cognitive batteries used in
the assessment of dementia [15] or brain injury [16] and
test–retest reliability in those with multiple sclerosis [17].
Although the CDR-CBT has been administered repeatedly
on a given test day to evaluate the time course of a drug’s
effects on cognitive functioning in healthy volunteers, and
in adults with dementia or Parkinson diseases [14, 18, 19],
to the best of our knowledge, there are no published reports
reporting test–retest reliability under conditions of multiple
assessments of the same battery on a single day. Normative
data from the CDR-CBT are based on testing of more than
4,000 healthy adult volunteers aged 18–87 years [14]. The
battery’s ability to detect attentional and memory impair-
ments has been validated, marked by sensitivity to changes
in cognitive functioning similar to other well-characterized
neuropsychiatric tests such as the Mini-Mental State
Examination and the Digit Symbol Substitution Test [17,
20]. A particular advantage of the CDR-CBT for use in
pharmacodynamics research is the ability to automatically
generate parallel but novel combinations of test items, so
that each time a task is administered, it is unique to the
participant, thereby minimizing the effect of learning-
specific stimulus items with repeated testing [21]. With
proper pre-study training to stabilize task performance
prior to on-study testing, practice effects can be overcome
[21]. In one acute pharmacodynamic investigation of
ginkgo biloba, repeat administration of the CDR-CBT over
6 h postdose was not associated with any apparent practice
effects among participants given placebo [19].
It is of interest to determine whether these assessments of
attention, as a measureable, integral and drug-responsive
component of EF, may be useful to also explore the time
course of treatment through the day in patients with ADHD.
The objective of the current placebo-controlled investigation
in adults with ADHD was to examine the sensitivity and
responsiveness of the CDR-CBT for assessing cognitive
impairment during treatment by describing the pharmaco-
dynamics of attention processing following administration
of a long-acting prodrug psychostimulant, lisdexamfetamine
dimesylate (LDX), and an IR psychostimulant (mixed
amphetamine salts IR; MAS-IR). LDX is indicated for the
treatment of ADHD in children (6–12 years), adolescents
(13–17 years), and adults [22]; MAS-IR is indicated for the
treatment of ADHD and narcolepsy [23].
2 Methods
2.1 Study Design
This was an exploratory, randomized, placebo-controlled,
double-blind, three-period crossover study in adults with
ADHD examining the sensitivity of the CDR-CBT battery
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to detect and finely discriminate pharmacodynamic effects
of psychostimulant treatment on cognitive functioning
(ClinicalTrials.gov identifier: NCT01010750). Participants
received LDX 50 mg/day, MAS-IR (various generics
available) 20 mg/day, and placebo (*7 a.m.) for 7 days
each, in randomized order (Fig. 1). These dosages were
chosen for this pilot study because both represent midrange
therapeutic dosages that are expected to produce roughly
comparable amphetamine levels with different pharmaco-
kinetic profiles; MAS-IR would produce a more rapid
increase in amphetamine levels but LDX would produce a
more sustained level of amphetamine over time. It was
hypothesized that these differential pharmacokinetic pro-
files would be reflected in the changes observed on the
computerized battery.
Cognitive functioning was assessed using the CDR-CBT
at -0.5 h (prior to any treatment) and 1, 2, 3, 4, 5, 8, 12,
14, and 16 h postdose on day 1 of the first treatment per-
iod, and on day 7 of each treatment period. Only the CDR
attention battery was used at 2 and 4 h postdose, whereas
the CDR full battery was used at all other timepoints. The
trial conformed to the principles of the Declaration of
Helsinki and its amendments as well as all local ethical and
legal requirements. Approval of the protocol and informed
consent documentation was obtained from the appropriate
institutional review board prior to study initiation. All
participants provided written and signed informed consent
prior to entry into the study.
2.2 Participants
Individuals with a history of successful treatment with an
amphetamine-based agent were recruited directly by the
principle investigator (Dr. Katic) from adult patients with
ADHD in his own practice; no external recruitment or
advertising was used. Participants were males and non-
pregnant, non-lactating females, aged 18–55 years, with a
primary diagnosis of ADHD (Adult ADHD Clinical
Diagnostic Scale, version 1.2) [24]. Entry requirements
included a baseline score C28 on the ADHD Rating Scale
IV (ADHD-RS-IV)[25] with adult prompts; a satisfactory
medical assessment with no significant or relevant abnor-
mality in medical history, physical examination, vital
signs, and laboratory evaluation; a body mass index
between 18.5 and 32.0 kg/m2, inclusive; and normal or
clinically insignificant screening electrocardiogram (ECG)
findings, as assessed by the investigator. Female partici-
pants were postmenopausal (12 consecutive months of
spontaneous amenorrhea and aged C51 years), surgically
sterile, or were using or agreed to use acceptable methods
of contraception and had a negative pregnancy test at
screening.
Excluded were individuals diagnosed with a severe co-
morbid Axis I or Axis II disorder, based on a psychiatric
evaluation that included the Mini International Neuro-
psychiatric Interview-Plus [26]; family history of sudden
cardiac death or personal history of cardiovascular dis-
ease or structural cardiac abnormality; personal history of
or current suicide risk, attempts, or ideations; docu-
mented allergy, hypersensitivity, or intolerance to
amphetamines, closely related compounds, or any of the
stated ingredients; history of seizures (other than infantile
febrile seizures), tic disorder, or diagnosis and/or family
history of Tourette disorder; and history (B12 months
prior) or screening evidence of substance abuse or
dependence.
Fig. 1 Study design flow chart.
Day 8 of each period is the
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2.3 Cognitive and Attention-Deficit/Hyperactivity
Disorder Symptom Outcomes
2.3.1 Cognitive Drug Research Computerized Battery
of Tests
The CDR-CBT is a 20-min, standardized and validated,
computerized battery of ten neuropsychometric tasks that
assess attention, vigilance, working memory, and EF. The
CDR-CBT yields five composite scores defined by factor
analysis [18]: power of attention (PoA), continuity of
attention, quality of working memory, quality of episodic
secondary memory, and speed of memory. For the current
analysis, the primary outcome was the PoA score derived
from the attention battery of the CDR-CBT. PoA is the sum
of three test scores: simple reaction time, choice reaction
time, and digit vigilance speed. For the simple reaction
time task, the participant was required to press a keyboard
button marked YES each time YES appeared on the screen.
For the choice reaction time task, the participant was
required to press buttons marked NO or YES, corre-
sponding to the words NO or YES presented on the screen.
For the digit vigilance speed task, the participant was
required to press a button marked YES when a randomly
selected digit was presented on the screen among a series
of non-target digits presented at the rate of 150/min; 45
targets were presented over 3 min. PoA scores are
expressed as milliseconds (ms); lower scores indicate rel-
atively better PoA.
2.3.2 Conners’ Adult ADHD Rating Scales-Self-Report:
Short Version
A secondary outcome was the Conners’ Adult ADHD
Rating Scales–Self-Report: Short Version (CAARS-S:S)
[27]. The CAARS-S:S is a 26-item questionnaire that
assesses symptoms of ADHD in persons aged C18 years,
which requires approximately 10 min to complete. The
CAARS-S:S was administered at baseline, on days 1 and 6
(at 2 and 14 h postdose) of period 1, and on days 6, 7, and
8 (at 2 and 14 h postdose) of periods 2 and 3.
2.4 Tertiary Pharmacodynamic Assessments
Other CDR-CBT measures associated with attention were
assessed as tertiary outcomes, including the composite
continuity of attention score and its component test scores
(digit vigilance targets detected, digit vigilance false
alarms, choice reaction time accuracy). Also examined
were additionally defined composite scores for cognitive
reaction time (combination of choice reaction time and
simple reaction time) and response variability [standard
deviations (SDs) for choice and simple reaction times, and
digit vigilance speed].
2.5 Safety Assessments
Safety assessments included treatment-emergent adverse
events (TEAEs), vital signs, physical examinations, clinical
laboratory investigations, and 12-lead ECG (screening
only). TEAEs were defined as adverse events (AEs) that
started or worsened from the first day of LDX treatment in
this study to the third day (inclusive) after treatment had
stopped and were categorized using the most recent version
of the Medical Dictionary for Regulatory Activities
(MedDRA, version 11.1).
2.6 Statistical Analysis
The composite PoA score was assessed in the pharmaco-
dynamic set that includes all participants who had taken C1
dose of investigational product and had C1 postdose
pharmacodynamic assessment. The composite PoA score
was summarized by treatment group. Difference in least
squares (LS) mean and its 95 % confidence interval
between active treatment and placebo were calculated
using a mixed-effect linear model, with treatment
sequence, period, and treatment as fixed effects and par-
ticipant within sequence group as a random effect. Addi-
tional CDT-CBR attention-related measures and CAARS-
S:S total and subscale raw scores and T scores were sub-
mitted to the same mixed-effect linear model as described
for the primary PoA outcome. This was an exploratory
analysis; therefore, statistics from the mixed-effect linear
model are for summary purposes rather than inferential
statistical comparisons among the treatment groups. Safety
was evaluated in all participants who had taken C1 dose of
investigational product and had C1 postdose safety
assessment based on frequency and severity of TEAEs and
review of individual values and summary statistics for vital




Table 1 summarizes demographic and baseline clinical
characteristics of the 18 enrolled and randomized partici-
pants (mean age 30.8 years); all were included in the
pharmacodynamic and safety analysis sets. One participant
withdrew prematurely because of AEs (see Sect. 3.5 for
details).
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3.2 Composite Power of Attention Scores
Prior to treatment, mean standard error (SE) PoA scores
ranged from 1,175.9 (46.61) to 1,361.2 (109.00) ms, scores
that are commensurate with a normative age [40 years
based on PoA assessment in more than 5,000 individuals.
At all post-administration timepoints, composite PoA
scores for LDX and MAS-IR were numerically less than
placebo (Fig. 2; Table 2), with the exception of 2 h post-
administration for LDX and 1 h post-administration for
MAS-IR. Maximum improvement in composite PoA scores
occurred at 5 h postdose at day 7 with both LDX and
MAS-IR (maximum LS mean difference [95 % CI] vs.
placebo of -150.0 [-235.41 to -64.50] ms and -79.8
[-165.72 to 6.21] ms, respectively; Fig. 3a, b). Perfor-
mance of individual component PoA tasks (simple reaction
time, digit vigilance speed, and choice reaction time) was
also improved (vs. placebo) 5 h postdose with LDX 50 mg
and MAS-IR 20 mg.
3.3 CAARS-S:S Outcomes
On day 6, prior to study medication administration, mean
(SE) CAARS-S:S ADHD Index scores were similar among
the treatment groups [range 20.2 (2.03)–21.2 (1.65)]. For
all 5 CAARS-S:S subscales, T scores when participants
were receiving LDX and MAS-IR were similar to those
when participants were receiving placebo (Fig. 4a, b).
3.4 Tertiary Pharmacodynamic Findings
Little change (vs. placebo) was observed in tertiary atten-
tion-related CDR-CBT outcomes (Fig. 3a, b) following
treatment with LDX or MAS-IR.
3.5 Safety
A total of 12 participants experienced a TEAE while taking
LDX (vs. nine with MAS-IR and eight with placebo). Most
TEAEs were mild or moderate; the most commonly
reported TEAEs across groups were dry mouth and head-
ache (17.6 % each) with placebo treatment, decreased
appetite and dry mouth (23.5 % each) with MAS-IR
treatment, and dry mouth and decreased appetite (33.3 and
16.7 %, respectively) with LDX treatment. Table 3 pre-
sents all TEAEs reported by C2 participants. No serious
TEAEs were reported. One female participant withdrew
from the study because of AEs (mild nausea and mild
vomiting). This participant was randomized to the LDX,
placebo, MAS-IR treatment sequence. Onset of these AEs
was 4 days after her last dose of LDX but she apparently
did not take her placebo doses; therefore, they were not
considered TEAEs. AEs resolved by 7 days after onset. For
Table 1 Demographic and baseline clinical characteristics (n = 18;
pharmacodynamic analysis set)
Characteristic Value
Age (years) 30.8 (10.75)
Male [n (%)] 11 (61.1)
Bodyweight (kg) 75.2 (14.15)






ADHD-RS-IV with adult prompts total score 36.9 (4.04)
Values are expressed as mean (SD) unless specified otherwise
ADHD-RS-IV attention-deficit/hyperactivity disorder rating scale IV,
BMI body mass index, SD standard deviation
Fig. 2 Least squares mean
(standard error) composite
power of attention scores across
16 h postdose, day 7
(pharmacodynamic set). A
slight horizontal shift of
datapoints was applied to
enhance readability. The error
bars represent standard error.




Effects on Cognition of LDX and MAS in Adult ADHD 151
all three treatment regimens, small postdose increases
occurred in mean pulse rate and systolic and diastolic blood
pressure (BP); however, the mean pulse rates and BP
associated with LDX or MAS-IR treatment were larger
than those associated with placebo (Fig. 5). No clinically
concerning changes in laboratory values or physical
examination findings were observed.
4 Discussion
At baseline, PoA scores for adults with ADHD indicated
impaired attention compared with age-normalized scores
for individuals without ADHD. PoA scores showed
response to treatment with LDX and MAS-IR compared
with placebo. However, CAARS-S:S total and subscale
scores did not differ between active treatment and placebo.
Additionally, tertiary CDR-CBT scores were largely
unchanged following treatment with either LDX or MAS-
IR. TEAEs and vital signs were consistent with previous
studies of psychostimulant therapy in adults with ADHD.
Current research surrounding the pathophysiology of
ADHD continues to emphasize the central role of impair-
ments in attention [28, 29]. Based on conventional neuro-
cognitive tests, attention deficits are reliably demonstrated
in at least a subset of patients with ADHD, as summarized
by Bush [28]. The current PoA findings add to the weight
of investigative evidence that now clearly indicates the
presence of attentional impairments that are responsive to
psychostimulant therapy. Participants in the current study,
with a mean age (SD) of 30.8 (10.75) years, although
untreated at baseline, exhibited age-normalized PoA scores
similar to those seen in individuals aged[40 years who do
not have ADHD, indicating clear impairment in attention.
Following treatment with LDX or MAS-IR, PoA scores
were improved at hour 3 postdose for LDX and hour 2
postdose for MAS-IR and persisted for both to hour 16
postdose. Generally, the PoA benefit seen with MAS-IR
was smaller and declined more rapidly than the effect
following LDX administration, which may reflect differing
doses of amphetamine with LDX and MAS-IR, and the IR
nature of MAS-IR. Results from a number of previous
trials that assessed the neurocognitive effects of psycho-
stimulant therapy in children [6], adolescents/young adults
[7], and adults [30] with ADHD yielded similar positive
outcomes as the one seen here. These and other prior
reports and the current findings indicate that psychostim-
ulant treatment reliably improves performance on neuro-
cognitive tasks that specifically assess response time and
vigilance in sustained attention. Improvements in perfor-
mance of attentional tasks with psychostimulant medica-
tion in individuals with ADHD is likely related to
normalization of brain activation and regional intercon-
nectivity that has been established with these medications,
particularly in areas such as inferior frontal and parietal
cortices and superior temporal cortex, believed to mediate
attention and task responding and to be involved in ADHD
pathophysiology [6, 31, 32]. It is of interest that tertiary
CDR-CBT outcomes examined currently, including conti-
nuity of attention, cognitive reaction time, and response
variability, were largely unchanged (vs. placebo) with
psychostimulant treatment. This is not unexpected, and is
similar to findings of prior investigations in children [6],
adolescents/young adults [7], and adults [30], suggesting
that psychostimulants may have a greater beneficial impact
on some aspects of attentional task performance (reaction
time and vigilance) than others (response variability).
The present investigation also provides further evidence
that the CDR-CBT may be a useful tool for assessing the
acute pharmacodynamic effects of medication on
Table 2 Relative improvement in composite power of attention scores with active treatment (vs. placebo), day 7
Hour on day 7 relative to dosing Difference in LS mean PoA (ms) [active treatment vs. placebo (95 % CI)]a
LDX 50 mg vs. placebo (n = 18) MAS-IR 20 mg vs. placebo (n = 17)
1 -10.7 (-87.04 to 65.57) 49.8 (-27.17 to 126.83)
2 18.4 (-114.05 to 150.94) -44.5 (-178.43 to 89.37)
3 -78.6 (-142.35 to -14.74) -75.9 (-140.03 to -11.80)
4 -81.5 (-141.27 to -21.74) -61.0 (-119.58 to -2.33)
5 -150.0 (-235.41 to -64.50) -79.8 (-165.72 to 6.21)
8 -89.8 (-146.86 to -32.69) -45.8 (-103.09 to 11.44)
12 -26.4 (-90.69 to 37.91) -23.3 (-87.82 to 41.16)
14 -72.1 (-123.31 to -20.79) -1.2 (-52.52 to 50.22)
16 -65.9 (-129.25 to -2.63) -16.4 (-79.96 to 47.07)
LDX lisdexamfetamine dimesylate, LS least squares, MAS-IR mixed amphetamine salts immediate release, PoA power of attention
a Differences between LS mean PoA scores (ms) with active treatment vs. placebo at the indicated timepoint and corresponding 95 % CIs,
calculated based on a mixed-effect linear model with sequence, period, and treatment as fixed effects and participant within sequence as a
random effect
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neurocognitive processes. In the current trial, the CDR-
CBT was sensitive enough to detect attention impairments
at baseline in medication-free patients with ADHD. Fol-
lowing study medication administration, the CDR-CBT
appeared sensitive enough to distinguish between two
active ADHD treatments with differing response profiles,
based on the composite PoA score. Unlike conventional
neuropsychiatric test batteries, the CDR-CBT takes
approximately 20 min to complete; this allows for rapid
and repeated assessment of the potential for response to
candidate drugs in adults with ADHD. The present finding
of significant PoA improvement with LDX and MAS-IR is
in line with prior studies showing improvements in sus-
tained attention with psychostimulant (methylphenidate)
treatment in children [6] and adolescents/young adults [7].
The secondary CAARS-S:S efficacy outcome was not
found to improve with psychostimulant therapy versus
placebo. This is not in line with findings from a number of
other trials in adults with ADHD in which the CAARS-S:S
was employed [33, 34]. The CAARS-S:S was not specifi-
cally designed for pharmacodynamics research, and its
degree of sensitivity for detecting changes in patient-per-
ceived ADHD symptom control over the acute postdose
period has not been characterized. To our knowledge, only
Fig. 3 Maximum relative improvement in Cognitive Drug Research
Computerized Battery of Tests (CDR-CBT) performance with active
treatment vs. placebo at 5 h postdose on day 7: a lisdexamfetamine
dimesylate 50 mg vs. placebo; b mixed amphetamine salts immediate
release 20 mg vs. placebo. LDX lisdexamfetamine dimesylate, LS
least squares, MAS-IR mixed amphetamine salts immediate release,
PoA power of attention
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one other investigation employed the CAARS-S:S to
describe the duration of acute symptom control with psy-
chostimulant medication. In that trial [33], patient-reported
CAARS-S:S scores were significantly improved from
baseline at 4 and 12 h postdose with MAS-XR (20–60 mg/
day) in adults with ADHD. The reason for the failure to
detect a positive change in CAARS-S:S score with active
treatment in the current investigation is unclear, but may be
related to dose and formulation of the psychostimulants
used, the timing of assessment, or the length of study
treatment (1 week per intervention). The prior investiga-
tion described by Weisler et al. [33] was a 4-week parallel-
group forced-dose titration study with three fixed doses of
MAS-XR (20, 40, or 60 mg/day) in adults with ADHD. By
contrast, in the present crossover investigation, single fixed
doses of LDX (50 mg) and MAS-IR (20 mg) were given
for 1 week each. Moreover, in the current investigation, the
CAARS-S:S was completed by participants at 2 and 14 h
post-treatment—postdosing times that may be associated
with minimal, subjective, patient-perceived symptom
control with the given doses/formulations. Future investi-
gations may characterize the sensitivity of the CAARS-S:S
across more frequent postdose times, comparing it with
other patient-reported ADHD-specific instruments.
Fig. 4 Differences in least squares mean (95 % CI) Conners’ Adult
ADHD Rating Scales-Self-Report: Short Version (CAARS-S:S)
T scores with active treatment vs. placebo on day 6: a lisdexamfeta-
mine dimesylate 50 mg vs. placebo; b mixed amphetamine salts
immediate release 20 mg vs. placebo. ADHD attention-deficit/
hyperactivity disorder, LDX lisdexamfetamine dimesylate, LS least
squares, MAS-IR mixed amphetamine salts immediate release
Table 3 Summary of treatment-emergent adverse events reported by C2 participants in any group (safety set)
System organ class preferred term, MedDRA,
version 11.1
LDX 50-mg group (n = 18)
[n (%)]
MAS-IR 20-mg group (n = 17)
[n (%)]
Placebo group (n = 17)
[n (%)]
Any TEAE 12 (66.7) 9 (52.9) 8 (47.1)
Decreased appetite 3 (16.7) 4 (23.5) 1 (5.9)
Dry mouth 6 (33.3) 4 (23.5) 3 (17.6)
Dyspnea 1 (5.6) 2 (11.8) 0
Feeling jittery 1 (5.6) 2 (11.8) 0
Headache 1 (5.6) 1 (5.9) 3 (17.6)
Heart rate increased 2 (11.1) 0 0
LDX lisdexamfetamine dimesylate, MAS-IR mixed amphetamine salts immediate release, MedDRA Medical Dictionary for Regulatory Activities,
TEAE treatment-emergent adverse event
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Fig. 5 Mean [standard
deviation] a pulse rate; b SBP;
and c DBP from predose to 16 h
postdose. A slight horizontal
shift of datapoints was applied
to enhance readability. DBP
diastolic blood pressure, LDX
lisdexamfetamine dimesylate,
MAS-IR mixed amphetamine
salts immediate release, SBP
systolic blood pressure
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In the present trial in adults with ADHD, the safety
profiles of LDX and MAS-IR were generally consistent
with prior studies. Most TEAEs were considered mild or
moderate and were consistent with those typically seen
with psychostimulant medications and in previous trials of
LDX in adults [10, 35]. Increases in pulse and BP with
LDX and MAS-IR were similar to and consistent with
those observed previously in adults [10, 35].
Some limitations of the study design should be consid-
ered. Participants were generally healthy; the pharmaco-
dynamics and safety of LDX in medically ill patients or
those with significant psychiatric co-morbidity were not
characterized. A 50-mg dose of LDX was examined; the
pharmacodynamic profile of LDX across a range of clini-
cally relevant doses is unknown. As this pilot study was
exploratory in nature, it was not sufficiently powered to
conduct parametric statistical comparisons among treat-
ment groups; thus, these data should be considered pre-
liminary. Larger studies, using a similar design in which it
is possible to compare treatment groups, are warranted.
5 Conclusions
In adults with ADHD, psychostimulant therapy with LDX
or MAS-IR (vs. placebo) was associated with acute post-
dose improvements in sustained attention, based on CDR-
CBT PoA continuous performance task scores. Improve-
ments with psychostimulant treatment were first seen by
2 h postdose with MAS-IR, 3 h with LDX, and for both
were consistently seen by 5 h and persisted for up to 16 h
postdose. CDR-CBT PoA appears to be sufficiently sensi-
tive to distinguish between an active ADHD treatment and
placebo, and may be sufficiently sensitive to distinguish
differing response properties of active treatments in an
appropriately designed clinical study.
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